Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

8521. Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: a systematic review

Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: a systematic review Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: a systematic review Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: a systematic review Roffe L, Schmidt K, Ernst E CRD summary This review investigated the use of coenzyme Q10 (CoQ10) supplementation to reduce the adverse effects of cancer treatments. It concluded that CoQ10 may offer some protection (...) against cardiotoxicity or liver toxicity but, because of the poor study quality, these results may be unreliable and further research is needed. The review methods were appropriate and its conclusions are likely to be reliable. Authors' objectives To summarise and critically evaluate the evidence available for oral supplementation with coenzyme Q10 (CoQ10) to improve the tolerability of cancer treatments. Searching AMED, British Nursing Index, CINAHL, DH-Data, EMBASE, MEDLINE and the Cochrane

DARE.2004

8522. Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis

Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis Kashyap S, Moher D, Fung M F, Rosenwaks Z CRD summary This review found that women treated with fertility medications may have no greater risk of ovarian cancer than untreated infertile women. While the review took steps to minimise bias (...) , the conclusions are limited because they are based on observational data and do not account for confounding factors such as treatment regimen, parity and specific infertility diagnosis. Authors' objectives To examine the relationship between assisted reproductive technology and ovarian cancer. Searching The Cochrane Controlled Trials Register, Cancerlit, MEDLINE , PubMed - in process, CINAHL and Current Contents were searched (all 1966 or inception to January 2003); the search terms were reported. The authors

DARE.2004

8523. Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months

Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months Conti S, Guercini F, Iorio A CRD summary This review (...) concluded that, compared with oral anticoagulants, long-term treatment (at least 3 months) with low molecular weight heparin for the prevention of recurrent venous thromboembolism does not reduce cancer mortality. The results should be treated with caution because they were derived from studies which the authors acknowledged had significant clinical differences, and which were of uncertain quality. In addition, most did not have cancer mortality as a primary end point. Authors' objectives To determine

DARE.2004

8524. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials

Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials Hotta K, Matsuo K, Ueoka H, Kiura K (...) , Tabata M, Tanimoto M CRD summary This meta-analysis of 8 RCTs compared platinum plus a new chemotherapy agent versus single new agent therapy alone for people with advanced non-small-cell lung cancer. The authors concluded that there is a modest but important improvement in survival associated with platinum-based therapy. The authors took steps to minimise bias and their conclusions appear reliable. Authors' objectives To compare platinum plus a single new chemotherapy agent versus the single new

DARE.2004

8525. Positron emission testing for six cancers (brain, cervical, small cell lung, ovarian, pancreatic and testicular): testicular cancer

Positron emission testing for six cancers (brain, cervical, small cell lung, ovarian, pancreatic and testicular): testicular cancer Positron emission testing for six cancers (brain, cervical, small cell lung, ovarian, pancreatic and testicular): testicular cancer Positron emission testing for six cancers (brain, cervical, small cell lung, ovarian, pancreatic and testicular): testicular cancer Matchar D B, Kulasingam S L, Havrilesky L, Mann L O, Myers E R, McCrory D C, Patwardhan M, Prosnitz R (...) CRD summary This review investigated the diagnostic accuracy of fluorodeoxyglucose positron emission tomography (FDG-PET) for testicular cancer. Given the poor-quality studies available, the authors appropriately state that it is difficult to draw firm conclusions about the use of FDG-PET in characterising residual disease. However, it may be overoptimistic to conclude that FDG-PET is superior to computed tomography for the initial staging of patients. Authors' objectives To investigate

DARE.2004

8526. Positron emission testing for six cancers (brain, cervical, small cell lung, ovarian, pancreatic and testicular): small-cell lung cancer

Positron emission testing for six cancers (brain, cervical, small cell lung, ovarian, pancreatic and testicular): small-cell lung cancer Positron emission testing for six cancers (brain, cervical, small cell lung, ovarian, pancreatic and testicular): small-cell lung cancer Positron emission testing for six cancers (brain, cervical, small cell lung, ovarian, pancreatic and testicular): small-cell lung cancer Matchar D B, Kulasingam S L, Havrilesky L, Mann L O, Myers E R, McCrory D C, Patwardhan (...) M, Prosnitz R CRD summary This review investigated fluorodeoxyglucose positron emission tomography (FDG-PET) compared with conventional imaging in the assessment of small-cell lung cancer (SCLC). The authors concluded that FDG-PET has a role in re-staging post-treatment and in diagnosing occult SCLC, but this requires confirmation due to the lack of comparative studies. The authors' conclusions are appropriately cautious given the limited data available. Authors' objectives To investigate

DARE.2004

8527. Positron emission testing for six cancers (brain, cervical, small cell lung, ovarian, pancreatic and testicular): brain cancer

Positron emission testing for six cancers (brain, cervical, small cell lung, ovarian, pancreatic and testicular): brain cancer Positron emission testing for six cancers (brain, cervical, small cell lung, ovarian, pancreatic and testicular): brain cancer Positron emission testing for six cancers (brain, cervical, small cell lung, ovarian, pancreatic and testicular): brain cancer Matchar D B, Kulasingam S L, Havrilesky L, Mann L O, Myers E R, McCrory D C, Patwardhan M, Prosnitz R CRD summary (...) This review investigated the performance of fluorodeoxyglucose positron emission tomography (FDG-PET) for the diagnosis of brain tumours. The authors concluded that FDG-PET may be valuable for distinguishing tumour from radiation necrosis, but this is tempered by results showing it was similar to single-photon emission tomography. The authors' conclusion is appropriately cautious given the limitations of the data available. Authors' objectives To investigate the diagnostic accuracy of fluorodeoxyglucose

DARE.2004

8528. Does this patient have a family history of cancer: an evidence-based analysis of the accuracy of family cancer history

Does this patient have a family history of cancer: an evidence-based analysis of the accuracy of family cancer history Does this patient have a family history of cancer: an evidence-based analysis of the accuracy of family cancer history Does this patient have a family history of cancer: an evidence-based analysis of the accuracy of family cancer history Murff H J, Spigel D R, Syngal S CRD summary This meta-analysis included 14 cohort studies that verified the accuracy of self-reported family (...) histories of site-specific cancer. The authors concluded that self-reported family histories are useful for breast and colon cancer in first-degree relatives, but the quality of family histories for other cancers and second-degree relatives is more variable. The search was limited to one database. Authors' objectives To assess the accuracy of self-reported information about people's family history of cancer. Searching Two authors searched MEDLINE independently for studies published in English between

DARE.2004

8529. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis

Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis Delbaldo C, Michiels S, Syz N, Soria J C, Le Chevalier T, Pignon J P CRD summary This reasonably (...) conducted review included 57 randomised controlled trials with 11,160 participants. The authors concluded that adding another drug to single-agent chemotherapy improved tumour response and survival for people with advanced inoperable non-small-cell lung cancer. Adding a third drug had a smaller effect on tumour response and no effect on survival. These conclusions are likely to be reliable. Authors' objectives To assess the effect of adding another drug to a single-agent or two-agent chemotherapy

DARE.2004

8530. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care

Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care National Institute for Clinical Excellence Record Status This is a bibliographic record (...) of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. London: National Institute for Clinical Excellence (NICE) 2004: 40 Authors' objectives This report provides guidelines on the classification and care of women at risk of familial breast cancer

Health Technology Assessment (HTA) Database.2004

8531. CT colonography ('virtual colonoscopy') for colon cancer screening

CT colonography ('virtual colonoscopy') for colon cancer screening CT colonography ('virtual colonoscopy') for colon cancer screening CT colonography ('virtual colonoscopy') for colon cancer screening BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes (...) the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. CT colonography ('virtual colonoscopy') for colon cancer screening. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 19(06). 2004 Authors' objectives This Assessment reviews evidence on the effectiveness of CT colonography as an alternative to colonoscopy for the purpose of colon cancer screening. Authors' conclusions Based

Health Technology Assessment (HTA) Database.2004

8532. Computer aided detection of breast cancer

Computer aided detection of breast cancer Computer aided detection of breast cancer Computer aided detection of breast cancer Institute for Clinical Systems Improvement Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institute for Clinical Systems Improvement. Computer aided detection of breast cancer. Bloomington MN: Institute for Clinical Systems Improvement (...) (ICSI) 2004: 18 Authors' objectives This review aims to assess the available evidence on the computer aided detection of breast cancer in mammography images. Authors' conclusions With regard to computer aided detection (CAD) of breast cancer, the ICSI Technology Assessment Committee finds: CAD causes no direct harm to patients. Misdiagnoses (false-positive or false-negative results) can lead to unnecessary follow-up testing, unnecessary patient anxiety, or delays in obtaining treatment. Lower

Health Technology Assessment (HTA) Database.2004

8533. Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer

Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer Kerr J Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Kerr J. Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer. Christchurch: New Zealand Health Technology Assessment (NZHTA) 2004: 49 Authors' objectives To review the evidence for the effectiveness of infrared thermography for population screening and diagnostic testing of breast cancer. - Topic

Health Technology Assessment (HTA) Database.2004

8534. Effectiveness of behavioral interventions to modify physical activity behaviors in general populations and cancer patients and survivors

Effectiveness of behavioral interventions to modify physical activity behaviors in general populations and cancer patients and survivors Effectiveness of behavioral interventions to modify physical activity behaviors in general populations and cancer patients and survivors Effectiveness of behavioral interventions to modify physical activity behaviors in general populations and cancer patients and survivors Holtzman J, Schmitz K, Babes G, Kane RL, Duval S, Wilt TJ, MacDonald RM, Rutks I Record (...) Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Holtzman J, Schmitz K, Babes G, Kane RL, Duval S, Wilt TJ, MacDonald RM, Rutks I. Effectiveness of behavioral interventions to modify physical activity behaviors in general populations and cancer patients and survivors. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report

Health Technology Assessment (HTA) Database.2004

8536. Impact of radiation wait times on risk of local recurrence of breast cancer: early stage cancer with no chemotherapy

Impact of radiation wait times on risk of local recurrence of breast cancer: early stage cancer with no chemotherapy Impact of radiation wait times on risk of local recurrence of breast cancer: early stage cancer with no chemotherapy Impact of radiation wait times on risk of local recurrence of breast cancer: early stage cancer with no chemotherapy Benk V, Fisher A, Glazer D, Paszat L Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Benk V, Fisher A, Glazer D, Paszat L. Impact of radiation wait times on risk of local recurrence of breast cancer: early stage cancer with no chemotherapy. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2004: 28 Authors' objectives The aim of this review was to assess the relationship between the risk of local recurrence (LR) of breast cancer and the waiting times

Health Technology Assessment (HTA) Database.2004

8537. The management of colorectal cancers

The management of colorectal cancers The management of colorectal cancers The management of colorectal cancers Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Centre for Reviews and Dissemination. The management of colorectal cancers. University of York. Effective Health Care 8(3). 2004 Authors (...) ' objectives This Effective Health Care bulletin summarises the research evidence on the management of colorectal cancers. Authors' conclusions Colorectal (bowel) cancer is the second most common cause of cancer death in England and Wales. Early detection and good management result in improved survival rates. Flexible sigmoidoscopy is the most appropriate initial investigation for the majority of patients with left sided colon symptoms. There is a clear correlation between colonoscopy completion rates

Health Technology Assessment (HTA) Database.2004

8538. Home-based chemotherapy for cancer: issues for patients, caregivers and the health care system

Home-based chemotherapy for cancer: issues for patients, caregivers and the health care system Home-based chemotherapy for cancer: issues for patients, caregivers and the health care system Home-based chemotherapy for cancer: issues for patients, caregivers and the health care system Boothroyd L, Lehoux P Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Boothroyd L, Lehoux P. Home-based chemotherapy for cancer: issues for patients, caregivers and the health care system. Montreal: Agence d'evaluation des technologies et des modes d'intervention en sante (AETMIS). AETMIS 04-02. 2004 Authors' objectives This study aims to assess the evidence concerning effectiveness, safety, patient preference and satisfaction, patient quality of life, and costs of home chemotherapy for cancer. Authors' conclusions Our review of the evidence

Health Technology Assessment (HTA) Database.2004

8539. Assessment of photodynamic therapy using porfimer sodium for esophageal, bladder and lung cancers

Assessment of photodynamic therapy using porfimer sodium for esophageal, bladder and lung cancers Assessment of photodynamic therapy using porfimer sodium for esophageal, bladder and lung cancers Assessment of photodynamic therapy using porfimer sodium for esophageal, bladder and lung cancers Erickson L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Erickson L. Assessment of photodynamic therapy using porfimer sodium for esophageal, bladder and lung cancers. Montreal: Agence d'evaluation des technologies et des modes d'intervention en sante (AETMIS). AETMIS 04-01. 2004 Authors' objectives The Ministre de la Sante et des Services Sociaux (MSSS) asked the Agence d'Evaluation des technologies et des modes dintervention en sante (AETMIS) to evaluate the efficacy of photodynamic therapy using porfimer sodium for its approved

Health Technology Assessment (HTA) Database.2004

8540. Measuring the quality of breast cancer care in women

Measuring the quality of breast cancer care in women Measuring the quality of breast cancer care in women Measuring the quality of breast cancer care in women Moher D, Schachter HM, Mamaladze V, Lewin G, Paszat L, Verma S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Moher D, Schachter HM, Mamaladze V, Lewin G, Paszat L, Verma S (...) . Measuring the quality of breast cancer care in women. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 105. 2004 Authors' objectives The purpose of this systematic review of the scientific-medical literature was to survey the range of quality measures assessing the quality of breast cancer care in women, and to characterize specific parameters potentially affecting their suitability for wider use. Specific emphasis was placed on diagnosis, treatment

Health Technology Assessment (HTA) Database.2004